Tekla World Healthcare Fund:THW

    Manage Alerts


    As of 6/21/2024

    52 Wk Avg$12.55$12.133.34%
    52 Wk High$14.30$12.8513.73%
    52 Wk Low$9.76$10.88-9.56%
    Regular Distribution TypeManaged Distribution
    Distribution Rate10.81%
    Distribution Amount$0.1167
    Distribution FrequencyMonthly
    Past performance is no guarantee of future results.

    Basic Information

    Investment Objective

    The Trust's investment objective is to seek current income and long-term capital appreciation.The Fund invests in equity and debt of healthcare companies. The Fund seeks to benefit from the earnings growth of the healthcare industry while capturing income.

    Capital Structure

    As of 6/21/2024

    Total Investment Exposure:$594.704M
    Total Common Assets:$474.704M
    Common Shares Outstanding:38,313,451

    As of 6/21/2024

    Preferred Share Assets:
    Total Debt (USD): $120.000M
    Regulatory Leverage (USD): $120.000M
    Effective Leverage (USD): $120.000M
    Effective Leverage (%): 20.18%
    Annual Expense Ratios

    As of 9/30/2023

      Per Common Share
    Management Fees1.25%
    Other Expenses:0.28%
    Baseline Expense: N/A
    Interest Expense:1.46%
    Total: 2.99%
    Fund Management

    Fund Sponsor
    abrdn Inc.

    Portfolio Managers
    Jason C. Akus, Daniel R. Omstead

    Category: Equity-Sector Equity
    Ticker: THW
    NAV Ticker: XTHWX
    Average Daily Volume (shares): 124,664
    Average Daily Volume (USD): $1.541M
    Inception Date: 6/26/2015
    Inception Share Price: $20.00
    Inception NAV: $19.06
    Tender Offer: No
    Term: No
    Fiscal Year End: September 30
    Third Party Links & Reports


    As of 6/21/2024

    Past performance is no guarantee of future results.
    Distribution History

    Enter declared start and end dates to display distribution history below. Income, Long Gain, Short Gain and ROC breakdowns will only be shown for the past year.

    Declared Date Payable Date Ex Date Distrib Amount Income Long Gain Short Gain ROC

    *Indicates a Special Distribution: A distribution disbursed in addition to the normal distributions paid out by the company.

    Key Information Regarding Distributions
    Avg. Earnings Per Share:
    As of 3/31/2024
    Annualized Distribution Rate on NAV:
    As of 6/21/2024
    Total Return on NAV (12 months):
    As of 6/21/2024
    Avg. Portfolio Coupon:
    As of 6/21/2024
    Total % Portfolio Effectively Leveraged:
    As of 6/21/2024

    Pricing Information

    Premium/Discount Information
    Past performance is no guarantee of future results.
    Premium/Discount Information

    As of 6/21/2024

    PeriodAvg Discount
    6 Month3.67%
    1 Year3.34%
    3 Year6.81%
    5 Year3.97%

    As of 6/21/2024

    3 Month-0.17
    6 Month0.42
    1 Year0.27
    Pricing History
    Date NAV Premium / Discount


    Calendar Year Total Returns

    As of 5/31/2024
    Category: Morningstar US CEF Sector Equity

    Past 20 Years

    Return YearPriceNAVCategory - PriceCategory - NAV
    Past performance is no guarantee of future results.
    Annualized Total Returns

    Returns for periods less than one year are cumulative rather than annualized

    As of 5/31/2024
    Category: Morningstar US CEF Sector Equity

    Past performance is no guarantee of future results.

    Portfolio Characteristics

    Portfolio Characteristics
    Average Coupon:
    As of 6/21/2024
    Number of Holdings:
    As of 4/30/2024
    Annual Portfolio Turnover:
    As of 9/30/2023
    Asset Allocation

    As of 4/30/2024

    Top Sectors

    As of 4/30/2024

    Defensive (Super Sector)77.18%
    Corporate (Super Sector)15.47%
    Corporate Bond13.36%
    Cyclical (Super Sector)4.60%
    Real Estate3.86%
    Cash Equivalents (Super Sector)2.59%
    Cash Equivalents2.59%
    Preferred Stock2.11%
    Basic Materials0.75%
    Top Holdings

    As of 4/30/2024

    HoldingValue% Portfolio
    UnitedHealth Group Inc$27.17M4.73%
    Eli Lilly and Co$25.64M4.46%
    Novo Nordisk A/S ADR$25.51M4.44%
    Merck & Co Inc$23.22M4.04%
    AstraZeneca PLC ADR$22.60M3.93%
    Johnson & Johnson$20.29M3.53%
    Roche Holding AG ADR$16.78M2.92%
    Thermo Fisher Scientific Inc$14.54M2.53%
    Sanofi SA ADR$13.02M2.26%
    Abbott Laboratories$12.88M2.24%
    Credit Quality

    As of 4/30/2024

    Maturity Breakdown

    As of 4/30/2024

    Country Allocation

    As of 4/30/2024

    Country% Portfolio
    United States - Equity60.20%
    United States - Fixed Income12.68%
    United Kingdom - Equity5.00%
    Switzerland - Equity4.92%
    Denmark - Equity4.83%
    France - Equity2.56%
    Japan - Equity1.35%
    Australia - Equity0.95%
    Germany - Equity0.88%
    Germany - Fixed Income0.68%
    Netherlands - Equity0.53%
    Israel - Equity0.44%
    China - Equity0.12%
    Canada - Equity0.01%

    Closed-end fund historical distribution sources have included net investment income, realized gains, and return of capital. For more detailed information on the distributions of a specific fund, please visit the sponsor's website.


    Distribution type sourced from Morningstar. In general, managed distributions may be sourced from net investment income, realized gains and return of capital. CEFConnect.com does not undertake to disclose specific information about closed-end fund distribution sources. For specific information about a fund's distribution sources, visit the fund sponsor's website.

    The following information applies to closed-end funds in general: Fund shares are not guaranteed or endorsed by any bank or other insured depository institution, and are not federally insured by the Federal Deposit Insurance Corporation. Shares of closed-end funds are subject to investment risks, including the possible loss of principal invested. There can be no assurance that fund objectives will be achieved. Closed-end funds frequently trade at a discount to their net asset value. NAV returns are net of fund expenses, and assume reinvestment of distributions.